BioPorto

Regulatory Filings • Nov 23, 2010

From January 2011, Dako will be distributing The NGAL Test - BioPorto's new
test for measuring acute kidney injury.

"Dako is the perfect partner for us," says Thea Olesen, CEO of BioPorto. "Dako
sells its products in more than 80 countries and they have decades of
experience in the launch and sale of diagnostic tests. In addition to ensuring
The NGAL Test a quick and direct access to most of the world market, the
contract with Dako will also contribute significantly to securing the right
level of technical support that is invaluable when launching a completely new
type of test. "

Dako is also pleased with the agreement: "The diagnosis of kidney disease is
already one of Dako's core areas in the Reagent Partnership Division, and with
access to The NGAL Test we will now get an opportunity to offer our customers a
popular new product, which both we and our customers look forward to "says
Christina Lindved Turner, Vice President of Reagent Partnership Division at
Dako.

The agreement does not prevent BioPorto from optimizing sales channels for The
NGAL Test. BioPorto is therefore continuing the discussion on cooperation with
the global diagnostics companies that are interested in marketing the kidney
injury marker as an important product in the portfolio of tests for their own
analytical instruments.

Further information:
Thea Olesen, CEO
Christina Thomsen, Investor Relations
Tel. +45 45 29 00 00, e-mail investor@bioporto.com